FDA Approval Alert: The Need-to-Know | Teclistamab-cqyv for Relapsed/Refractory Multiple Myeloma

In October 22, the FDA granted accelerated approval to teclistamab-cqvy for patients with relapsed/refractory multiple myeloma.

Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.
Joseph Mikhael, MD, Discusses the FDA’s Approval of Teclistimab-cqyv in Relapsed/Refractory Multiple Myeloma
Video
Oct 26, 2022 4:00 PM
Teclistimab and similar bispecifics can have a prolific impact on patients with heavily relapsed multiple myeloma in the short term and possibly in earlier relapses in the long term, according to Joseph Mikhael, MD.
FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma
FDA Grants Accelerated Approval to Teclistamab-cqyv in Relapsed/Refractory Multiple Myeloma
Article
Oct 25, 2022 7:25 PM
Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval to teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.